$4.17
+0.19 (+4.77%)
Open$3.94
Previous Close$3.98
Day High$4.28
Day Low$3.75
52W High$37.58
52W Low$17.20
Volume—
Avg Volume256.7K
Market Cap198.52M
P/E Ratio34.73
EPS$0.86
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+653.2% upside
Current
$4.17
$4.17
Target
$31.41
$31.41
$26.29
$31.41 avg
$48.84
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 92.27M | 83.15M | 89.97M |
| Net Income | 5.58M | 4.38M | 5.69M |
| Profit Margin | 6.1% | 5.3% | 6.3% |
| EBITDA | 11.07M | 10.58M | 10.22M |
| Free Cash Flow | 5.66M | 4.59M | 4.29M |
| Rev Growth | -8.1% | +18.1% | +3.5% |
| Debt/Equity | 0.85 | 0.76 | 0.75 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |